This year’s Super Bowl and an often controversial NFL season are behind us and I’d like to congratulate the New England Patriots on the nice win. (Seattle, you put up a good fight but that was a pretty risky call at the last minute!) But, even as the win by the Pats fades, a new controversy has stirred. Seahawks defensive end Cliff Avril exited the Super Bowl in the third quarter after being diagnosed with a concussion. Patriots wide receiver Julian Edelman passed a concussion test during the Super Bowl on Sunday, allowing him to continue to play, but it could have just as easily gone the other way. Continue reading
Last weekend, I attended the major wine fair in Lille, France. Bottles of St Emilion Grand Cru Classé, Chateauneuf du Pape, St Joseph, Saumur-Champigny found their way to my cellar in preparation for the sumptuous dinners I’m planning around Christmas. Young red wines are good for cardiovascular system, whereas, an excess of good wine and good food is not a good idea for a long and healthy life. Continue reading
I’ve had many conversations with customers who struggle with their reality that it can be very costly and time-consuming for manufacturers to predict the performance of medical devices. They wonder how to address these problems using modelling and simulation to help evaluate devices at an early stage of their development. Given the recent success of the Medical Device Innovation Summit, it was clear to me that there are a lot of exciting developments taking place by using ANSYS for this purpose, whether it involves orthopaedic implants, stents or other devices. Continue reading
Cell-culture bioreactors lie at the heart of the processes used to produce large-molecule, protein-based therapeutics. In cell culture, mammalian cells are grown outside the human/plant body. These cells produce therapeutic proteins and antibodies. This is much easier said than done. In fact, cells do not cooperate much when they are grown outside the (human or plant) body. The question then is: Why is it so difficult for cells in culture to have the same physiological function in laboratory as in our body? Continue reading
Two weeks ago, while visiting some partners of the ANGIOVISION project, I had the unique opportunity to be in the operating room to attend an open heart surgery. It was fascinating to see live what we have been simulating for years. The replacement of the calcified heart valve combined with some bypass is a delicate surgery that necessitates extra corporeal blood circulation. I found myself very aware of the anxiety felt by the patient’s family, as my father-in-law had a similar operation a few months ago.
Despite the complexity of the situation, I was amazed by the serenity of the surgeon moving from step-to-step with professionalism, expertise and extreme calm, taking a few seconds to show me in reality what I usually see on the screen. For sure, the most moving time was when they brought the heart back to working temperature and watching this robust pump spontaneously feeding life into the body again. Continue reading
On September 11th to 13th, I will be traveling to Washington, DC to present at the Frontiers in Medical Devices conference which ANSYS is helping to sponsor. The FDA and ASME are co-sponsoring this event that is focused on the application of computer modeling and simulation in the biomedical industry.
This conference is designed to present new research, foster discussion of the barriers to implementation of computer modeling and to promote the use of modeling for medical device applications. Conference tracks range from patient-specific to population modeling, and from novel computational methods to computational models as medical devices. Continue reading
Using engineering simulation techniques for biomedical R&D is becoming more and more commonplace for many healthcare applications. For example, accurate description and assessment of blood flow features are crucial to understand the genesis and progression of cardiovascular diseases. While noninvasive measurement techniques have grown more advanced in resolving flow details, there are still problems with accuracy and resolution. Flow features such as wall shear stress, which depends on the velocity gradient at the arterial wall, cannot be measured with significant accuracy using today’s measurement techniques. In the Computational Biofluid Research Group at Linköping University, we are using simulation to gain a better understand of blood flow. Continue reading
About a quarter of a teaspoon, or 1.25 grams, of sugar. That is the difference in the quantity of sugar in the blood between a healthy individual and one who has been diagnosed with diabetes mellitus. Since I have a genetic predisposition for diabetes, I was not surprised to be diagnosed with it recently. The diagnosis brings with it restrictions, especially in diet. But advances in modern medicine and medical technology have ensured that patients can lead normal lives. This blog deals with engineering that has made some of this possible.
In a healthy individual, the concentration of sugar in the blood is maintained (within a narrow range) through a complex system of biochemical reactions. In individuals afflicted with diabetes, this healthy status is disturbed due to various causes and results in higher blood sugar concentrations. If not treated, diabetes can lead to damage to the heart, kidney, feet and retina — organs where bloodflow through fine capillaries is involved. The aim of diabetes treatment is to restore blood sugar concentrations to a healthy range by a combination of changes in diet, medication, lifestyle as well as by adding insulin and providing information. Continue reading